In8Bio (INAB) Common Equity (2020 - 2026)

In8Bio has disclosed Common Equity across 7 years of filings, most recently posting $18.4 million for Q2 2026.

• In Q2 2026, Common Equity rose 20.5% year-over-year to $18.4 million; the TTM figure through Jun 2026 stood at $18.4 million (up 20.5% YoY), while the FY2025 annual figure was $27.6 million, up 90.34% from the prior year.
• Common Equity came in at $18.4 million for Q2 2026 at In8Bio, down from $22.8 million in the prior quarter.
• In the past five years, Common Equity ranged from a high of $490.0 million in Q1 2024 to a low of $8.6 million in Q3 2024.
• Average Common Equity over 5 years is $46.1 million, with a median of $20.1 million recorded in 2023.
• Year-over-year, Common Equity jumped 2818.75% in 2024 and plunged 97.17% in 2025.
• Over 5 years, Common Equity stood at $22.7 million in 2022, then climbed by 9.7% to $24.9 million in 2023, then plunged by 41.94% to $14.5 million in 2024, then surged by 90.34% to $27.6 million in 2025, then sank by 33.37% to $18.4 million in 2026.
• Per Business Quant data, the three most recent Common Equity figures were $18.4 million in Q2 2026, $22.8 million in Q1 2026, and $27.6 million in Q4 2025.